FULL TEST BANK FOR
LEHNE’S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSES AND PHYSICIAN ASSISTANTS
3RD EDITION BY JACQUELINE BURCHUM; LAURA D. ROSENTHAL | 2025|
,unit i introduction .................................................................................................................................................. 5
CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK.................................................................................................................. 5
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ....................................................................................... 8
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY .......................................................................................... 12
unit ii basic principles of pharmacology ............................................................................................................... 16
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS .................................................................. 16
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ......................................................................................... 24
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES ...................................................................................................... 31
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ................................................................... 37
unit iii drug therapy across the life span .............................................................................................................. 44
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING .................................................................................. 44
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................................................. 50
CHAPTER 10: DRUG THERAPY IN GERIATRIC ........................................................................................................................ 56
unit iv peripheral nervous system drugs .............................................................................................................. 64
CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .................................................................................................64
CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM .........................................................................................68
CHAPTER 14 MUSCARINIC ANTAGONISTS ........................................................................................................................... 78
CHAPTER 15: ADRENERGIC AGONISTS ............................................................................................................................... 83
CHAPTER 16: ADRENERGIC ANTAGONISTS .......................................................................................................................... 89
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................................................... 98
unit v central nervous system drugs .................................................................................................................. 104
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY .......................................................................104
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ...............................................................................................................109
CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE ...............................................................................................................114
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS ..................................................................................................................120
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY ..................................................................................................125
chapter 23: local anesthetics ............................................................................................................................. 131
CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS .................................137
CHAPTER 25: DRUGS FOR HEADACHE ..............................................................................................................................145
UNIT VII PSYCHOTHERAPEUTIC DRUGS.............................................................................................................................153
CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ..............................................................................153
CHAPTER 27: ANTIDEPRESSANTS....................................................................................................................................161
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER ...................................................................................................................168
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS .......................................................................................................................174
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS .........................................................................................................179
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY DISORDER..................................185
unit viii substance use disorders ........................................................................................................................ 191
CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ........................................................................................................191
CHAPTER 33: DRUG ABUSE II: ALCOHOL...........................................................................................................................196
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING......................................................................................................203
CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE ..................................................209
unit ix drugs that affect the heart, blood vessels, blood, and blood volume ...................................................... 219
, CHAPTER 36: REVIEW OF HEMODYNAMICS ......................................................................................................................219
CHAPTER 37: DIURETICS...............................................................................................................................................223
CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM .................................................................229
CHAPTER 39: CALCIUM CHANNEL BLOCKERS....................................................................................................................236
CHAPTER 40: VASODILATORS ........................................................................................................................................239
CHAPTER 41: DRUGS FOR HYPERTENSION ........................................................................................................................245
CHAPTER 42: DRUGS FOR HEART FAILURE ........................................................................................................................256
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS .........................................................................................................................267
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP NORMALIZE CHOLESTEROL AND
TRIGLYCERIDE LEVELS...................................................................................................................................................278
CHAPTER 45: DRUGS FOR ANGINA PECTORIS ....................................................................................................................288
CHAPTER 46: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ..........................................................................297
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS ................................................................................................................307
unit x drugs for endocrine disorders .................................................................................................................. 315
CHAPTER 48: DRUGS FOR DIABETES MELLITUS ..................................................................................................................315
CHAPTER 49: DRUGS FOR THYROID DISORDERS .................................................................................................................324
unit xi reproductive health ................................................................................................................................ 332
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE APPLICATIONS ..............................332
CHAPTER 51: BIRTH CONTROL .......................................................................................................................................336
CHAPTER 52: ANDROGENS ...........................................................................................................................................345
CHAPTER 53: DRUGS FOR ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA ..........................................................351
CHAPTER 54. DRUGS FOR SEXUAL DYSFUNCTION ..............................................................................................................354
CHAPTER 55. TRANSGENDER HEALTH .............................................................................................................................359
CHAPTER 56: REVIEW OF THE IMMUNE SYSTEM ................................................................................................................365
CHAPTER 57: CHILDHOOD IMMUNIZATION.......................................................................................................................370
CHAPTER 58: ANTIHISTAMINES ......................................................................................................................................378
CHAPTER 59: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND ACETAMINOPHEN........................385
CHAPTER 60: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ..........................................................................................393
unit xiv respiratory tract drugs .......................................................................................................................... 401
CHAPTER 61: DRUG THERAPY OF RHEUMATOID ARTHRITIS ..................................................................................................401
CHAPTER 62: DRUG THERAPY OF GOUT ...........................................................................................................................405
CHAPTER 63: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION .......................................................................410
unit xiv respiratory tract drugs .......................................................................................................................... 419
CHAPTER 64: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE ..............................................................419
CHAPTER 65: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS.......................................................................................429
unit xiv respiratory tract drugs .......................................................................................................................... 437
CHAPTER 66: DRUGS FOR PEPTIC ULCER DISEASE ...............................................................................................................437
CHAPTER 67: LAXATIVES ..............................................................................................................................................444
CHAPTER 68: OTHER GASTROINTESTINAL DRUGS ...............................................................................................................451
unit xviii cancer therapy .................................................................................................................................... 461
CHAPTER 69: VITAMINS ...............................................................................................................................................461
CHAPTER 70: DRUGS FOR WEIGHT LOSS ..........................................................................................................................468
CHAPTER 71: COMPLEMENTARY AND ALTERNATIVE THERAPIES ............................................................................................475
,unit xvii therapy for infectious and parasitic diseases ........................................................................................ 480
CHAPTER 72: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY .............................................................................................480
CHAPTER 73: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS .........................................................................486
CHAPTER 74: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS .....................................................................493
CHAPTER 75: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS........................................................................................500
CHAPTER 76: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ................................................................510
CHAPTER 77: SULFONAMIDES AND TRIMETHOPRIM ...........................................................................................................519
CHAPTER 78: DRUG THERAPY OF URINARY TRACT INFECTIONS ..............................................................................................526
CHAPTER 79: ANTIMYCOBACTERIAL AGENTS.....................................................................................................................534
CHAPTER 80: MISCELLANEOUS ANTIBACTERIAL DRUGS .......................................................................................................543
CHAPTER 81: ANTIFUNGAL AGENTS ................................................................................................................................548
CHAPTER 82: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS............................................................................559
CHAPTER 83: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION AND RELATED OPPORTUNISTIC INFECTIONS ...................................567
CHAPTER 84: DRUG THERAPY OF SEXUALLY TRANSFERWISE DISEASES.....................................................................................574
CHAPTER 85: ANTHELMINTICS, ANTIPROTOZOAL DRUGS, AND ECTOPARASITICIDES ...................................................................579
unit xviii cancer therapy .................................................................................................................................... 584
CHAPTER 86 INTRODUCTION TO IMMUNOMODULATORS ....................................................................................................584
CHAPTER 87: SUPPORTIVE CARE OF PATIENTS RECEIVING ANTICANCER DRUGS .........................................................................590
CHAPTER 88: DRUGS FOR CANCER PAIN...........................................................................................................................598
unit xix drugs for eyes, ears, and skin ................................................................................................................ 607
CHAPTER 89: DRUGS FOR THE EYE ..................................................................................................................................607
CHAPTER 90: DRUGS FOR THE SKIN ................................................................................................................................614
unit xix drugs for eyes, ears, and skin ................................................................................................................ 625
CHAPTER 91: DRUGS FOR THE EAR .................................................................................................................................625
unit xx drug therapy in acute care ..................................................................................................................... 631
CHAPTER 92: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS .................................................................631
CHAPTER 93: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION .............................................................................637
CHAPTER 94: ADDITIONAL ACUTE CARE DRUGS .................................................................................................................644
,Unit i introduction
Chapter 1: prescriptive authority test bank
Multiple choice
1. An aprn works in a urology clinic under the supervision of a physician who does not restrict the
types of medications the aprn is allowed to prescribe. State law does not require the aprn to practice
under physician supervision. How would the aprn’s prescriptive authority be described?
A. Full authority
B. Independent
C. Without limitation
D. Limited authority
Answer: b
The aprn has independent prescriptive authority because the regulating body does not require that the
aprn work under physician supervision. Full prescriptive authority gives the provider the right to
prescribe independently and without limitation. Limited authority places restrictions on the types of
drugs that can be prescribed.dif: cognitive level: comprehensionref: p. 1top: nursing process: i msc:
nclex client needs category: physiologic integrity: pharmacologic and parenteral therapies
2. Which factors increase the need for aprns to have full prescriptive authority?
A. More patients will have access to health care.
B. Enrollment in medical schools is predicted to decrease.
C. Physician’s assistants are being utilized less often.
D. Aprn education is more complex than education for physicians.
Answer: a
Implementation of the affordable care act has increased the number of individuals with health care
coverage, and thus the number who have access to health care services. The increase in the number of
patients creates the need for more providers with prescriptive authority. Aprns can fill this practice
,gap.dif: cognitive level: comprehension ref: p. 2top: nursing process: implementation msc: nclex client
needs category: physiologic integrity: pharmacologic and parenteral therapies
3. Which factors could be attributed to limited prescriptive authority for aprns? Select all that
apply.
A. Inaccessibility of patient care
B. Higher health care costs
C. Higher quality medical treatment
D. Improved collaborative care
E. Enhanced health literacy
Answer: a , b
Limiting prescriptive authority for aprns can create barriers to quality, affordable, and accessible patient
care. It may also lead to poor collaboration among providers and higher health care costs. It would not
directly impact patient’s health literacy. Dif: cognitive level: comprehension ref:
P. 2top: nursing process: implementation msc: nclex client needs category: physiologic integrity:
pharmacologic and parenteral therapies
4. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
E. Limiting provision can decrease health care affordability.
, Answer: a , c , d
Aprns are educated to practice and prescribe independently without supervision. National examinations
validate the ability to provide safe and competent care. Licensure ensures compliance with standards to
promote public health and safety. Limited prescriptive authority creates numerous barriers to quality,
affordable, and accessible patient care.dif: cognitive level: comprehensionref: pp. 1-2top: nursing
process: implementation msc: nclex client needs category: physiologic integrity: pharmacologic and
parenteral therapies
5. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
Answer: a , c , d
Aprns are educated to practice and prescribe independently without supervision. National examinations
validate the ability to provide safe and competent care. Licensure ensures compliance with standards to
promote public health and safety. Limited prescriptive authority creates numerous barriers to quality,
affordable, and accessible patient care.dif: cognitive level:
Comprehensionref: pp. 1-2top: nursing process: implementation msc: nclex client needs
category: physiologic integrity: pharmacologic and parenteral therapies
6. A family nurse practitioner practicing in maine is hired at a practice across state lines in virginia.
Which aspect of practice may change for the aprn?
A. The aprn will have less prescriptive authority in the new position.
B. The aprn will have more prescriptive authority in the new position.
LEHNE’S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSES AND PHYSICIAN ASSISTANTS
3RD EDITION BY JACQUELINE BURCHUM; LAURA D. ROSENTHAL | 2025|
,unit i introduction .................................................................................................................................................. 5
CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK.................................................................................................................. 5
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ....................................................................................... 8
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY .......................................................................................... 12
unit ii basic principles of pharmacology ............................................................................................................... 16
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS .................................................................. 16
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ......................................................................................... 24
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES ...................................................................................................... 31
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ................................................................... 37
unit iii drug therapy across the life span .............................................................................................................. 44
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING .................................................................................. 44
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................................................. 50
CHAPTER 10: DRUG THERAPY IN GERIATRIC ........................................................................................................................ 56
unit iv peripheral nervous system drugs .............................................................................................................. 64
CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .................................................................................................64
CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM .........................................................................................68
CHAPTER 14 MUSCARINIC ANTAGONISTS ........................................................................................................................... 78
CHAPTER 15: ADRENERGIC AGONISTS ............................................................................................................................... 83
CHAPTER 16: ADRENERGIC ANTAGONISTS .......................................................................................................................... 89
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................................................... 98
unit v central nervous system drugs .................................................................................................................. 104
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY .......................................................................104
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ...............................................................................................................109
CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE ...............................................................................................................114
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS ..................................................................................................................120
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY ..................................................................................................125
chapter 23: local anesthetics ............................................................................................................................. 131
CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS .................................137
CHAPTER 25: DRUGS FOR HEADACHE ..............................................................................................................................145
UNIT VII PSYCHOTHERAPEUTIC DRUGS.............................................................................................................................153
CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ..............................................................................153
CHAPTER 27: ANTIDEPRESSANTS....................................................................................................................................161
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER ...................................................................................................................168
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS .......................................................................................................................174
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS .........................................................................................................179
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY DISORDER..................................185
unit viii substance use disorders ........................................................................................................................ 191
CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ........................................................................................................191
CHAPTER 33: DRUG ABUSE II: ALCOHOL...........................................................................................................................196
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING......................................................................................................203
CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE ..................................................209
unit ix drugs that affect the heart, blood vessels, blood, and blood volume ...................................................... 219
, CHAPTER 36: REVIEW OF HEMODYNAMICS ......................................................................................................................219
CHAPTER 37: DIURETICS...............................................................................................................................................223
CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM .................................................................229
CHAPTER 39: CALCIUM CHANNEL BLOCKERS....................................................................................................................236
CHAPTER 40: VASODILATORS ........................................................................................................................................239
CHAPTER 41: DRUGS FOR HYPERTENSION ........................................................................................................................245
CHAPTER 42: DRUGS FOR HEART FAILURE ........................................................................................................................256
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS .........................................................................................................................267
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP NORMALIZE CHOLESTEROL AND
TRIGLYCERIDE LEVELS...................................................................................................................................................278
CHAPTER 45: DRUGS FOR ANGINA PECTORIS ....................................................................................................................288
CHAPTER 46: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ..........................................................................297
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS ................................................................................................................307
unit x drugs for endocrine disorders .................................................................................................................. 315
CHAPTER 48: DRUGS FOR DIABETES MELLITUS ..................................................................................................................315
CHAPTER 49: DRUGS FOR THYROID DISORDERS .................................................................................................................324
unit xi reproductive health ................................................................................................................................ 332
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE APPLICATIONS ..............................332
CHAPTER 51: BIRTH CONTROL .......................................................................................................................................336
CHAPTER 52: ANDROGENS ...........................................................................................................................................345
CHAPTER 53: DRUGS FOR ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA ..........................................................351
CHAPTER 54. DRUGS FOR SEXUAL DYSFUNCTION ..............................................................................................................354
CHAPTER 55. TRANSGENDER HEALTH .............................................................................................................................359
CHAPTER 56: REVIEW OF THE IMMUNE SYSTEM ................................................................................................................365
CHAPTER 57: CHILDHOOD IMMUNIZATION.......................................................................................................................370
CHAPTER 58: ANTIHISTAMINES ......................................................................................................................................378
CHAPTER 59: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND ACETAMINOPHEN........................385
CHAPTER 60: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ..........................................................................................393
unit xiv respiratory tract drugs .......................................................................................................................... 401
CHAPTER 61: DRUG THERAPY OF RHEUMATOID ARTHRITIS ..................................................................................................401
CHAPTER 62: DRUG THERAPY OF GOUT ...........................................................................................................................405
CHAPTER 63: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION .......................................................................410
unit xiv respiratory tract drugs .......................................................................................................................... 419
CHAPTER 64: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE ..............................................................419
CHAPTER 65: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS.......................................................................................429
unit xiv respiratory tract drugs .......................................................................................................................... 437
CHAPTER 66: DRUGS FOR PEPTIC ULCER DISEASE ...............................................................................................................437
CHAPTER 67: LAXATIVES ..............................................................................................................................................444
CHAPTER 68: OTHER GASTROINTESTINAL DRUGS ...............................................................................................................451
unit xviii cancer therapy .................................................................................................................................... 461
CHAPTER 69: VITAMINS ...............................................................................................................................................461
CHAPTER 70: DRUGS FOR WEIGHT LOSS ..........................................................................................................................468
CHAPTER 71: COMPLEMENTARY AND ALTERNATIVE THERAPIES ............................................................................................475
,unit xvii therapy for infectious and parasitic diseases ........................................................................................ 480
CHAPTER 72: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY .............................................................................................480
CHAPTER 73: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS .........................................................................486
CHAPTER 74: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS .....................................................................493
CHAPTER 75: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS........................................................................................500
CHAPTER 76: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ................................................................510
CHAPTER 77: SULFONAMIDES AND TRIMETHOPRIM ...........................................................................................................519
CHAPTER 78: DRUG THERAPY OF URINARY TRACT INFECTIONS ..............................................................................................526
CHAPTER 79: ANTIMYCOBACTERIAL AGENTS.....................................................................................................................534
CHAPTER 80: MISCELLANEOUS ANTIBACTERIAL DRUGS .......................................................................................................543
CHAPTER 81: ANTIFUNGAL AGENTS ................................................................................................................................548
CHAPTER 82: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS............................................................................559
CHAPTER 83: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION AND RELATED OPPORTUNISTIC INFECTIONS ...................................567
CHAPTER 84: DRUG THERAPY OF SEXUALLY TRANSFERWISE DISEASES.....................................................................................574
CHAPTER 85: ANTHELMINTICS, ANTIPROTOZOAL DRUGS, AND ECTOPARASITICIDES ...................................................................579
unit xviii cancer therapy .................................................................................................................................... 584
CHAPTER 86 INTRODUCTION TO IMMUNOMODULATORS ....................................................................................................584
CHAPTER 87: SUPPORTIVE CARE OF PATIENTS RECEIVING ANTICANCER DRUGS .........................................................................590
CHAPTER 88: DRUGS FOR CANCER PAIN...........................................................................................................................598
unit xix drugs for eyes, ears, and skin ................................................................................................................ 607
CHAPTER 89: DRUGS FOR THE EYE ..................................................................................................................................607
CHAPTER 90: DRUGS FOR THE SKIN ................................................................................................................................614
unit xix drugs for eyes, ears, and skin ................................................................................................................ 625
CHAPTER 91: DRUGS FOR THE EAR .................................................................................................................................625
unit xx drug therapy in acute care ..................................................................................................................... 631
CHAPTER 92: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS .................................................................631
CHAPTER 93: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION .............................................................................637
CHAPTER 94: ADDITIONAL ACUTE CARE DRUGS .................................................................................................................644
,Unit i introduction
Chapter 1: prescriptive authority test bank
Multiple choice
1. An aprn works in a urology clinic under the supervision of a physician who does not restrict the
types of medications the aprn is allowed to prescribe. State law does not require the aprn to practice
under physician supervision. How would the aprn’s prescriptive authority be described?
A. Full authority
B. Independent
C. Without limitation
D. Limited authority
Answer: b
The aprn has independent prescriptive authority because the regulating body does not require that the
aprn work under physician supervision. Full prescriptive authority gives the provider the right to
prescribe independently and without limitation. Limited authority places restrictions on the types of
drugs that can be prescribed.dif: cognitive level: comprehensionref: p. 1top: nursing process: i msc:
nclex client needs category: physiologic integrity: pharmacologic and parenteral therapies
2. Which factors increase the need for aprns to have full prescriptive authority?
A. More patients will have access to health care.
B. Enrollment in medical schools is predicted to decrease.
C. Physician’s assistants are being utilized less often.
D. Aprn education is more complex than education for physicians.
Answer: a
Implementation of the affordable care act has increased the number of individuals with health care
coverage, and thus the number who have access to health care services. The increase in the number of
patients creates the need for more providers with prescriptive authority. Aprns can fill this practice
,gap.dif: cognitive level: comprehension ref: p. 2top: nursing process: implementation msc: nclex client
needs category: physiologic integrity: pharmacologic and parenteral therapies
3. Which factors could be attributed to limited prescriptive authority for aprns? Select all that
apply.
A. Inaccessibility of patient care
B. Higher health care costs
C. Higher quality medical treatment
D. Improved collaborative care
E. Enhanced health literacy
Answer: a , b
Limiting prescriptive authority for aprns can create barriers to quality, affordable, and accessible patient
care. It may also lead to poor collaboration among providers and higher health care costs. It would not
directly impact patient’s health literacy. Dif: cognitive level: comprehension ref:
P. 2top: nursing process: implementation msc: nclex client needs category: physiologic integrity:
pharmacologic and parenteral therapies
4. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
E. Limiting provision can decrease health care affordability.
, Answer: a , c , d
Aprns are educated to practice and prescribe independently without supervision. National examinations
validate the ability to provide safe and competent care. Licensure ensures compliance with standards to
promote public health and safety. Limited prescriptive authority creates numerous barriers to quality,
affordable, and accessible patient care.dif: cognitive level: comprehensionref: pp. 1-2top: nursing
process: implementation msc: nclex client needs category: physiologic integrity: pharmacologic and
parenteral therapies
5. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
Answer: a , c , d
Aprns are educated to practice and prescribe independently without supervision. National examinations
validate the ability to provide safe and competent care. Licensure ensures compliance with standards to
promote public health and safety. Limited prescriptive authority creates numerous barriers to quality,
affordable, and accessible patient care.dif: cognitive level:
Comprehensionref: pp. 1-2top: nursing process: implementation msc: nclex client needs
category: physiologic integrity: pharmacologic and parenteral therapies
6. A family nurse practitioner practicing in maine is hired at a practice across state lines in virginia.
Which aspect of practice may change for the aprn?
A. The aprn will have less prescriptive authority in the new position.
B. The aprn will have more prescriptive authority in the new position.
